SCHEMBL23348448

SCHEMBL23348448

C[C@@]1(OC(=O)c2ccccc2)[C@H](OC(=O)c2ccccc2)C(COC(=O)c2ccccc2)O[C@H]1n1ccc(=O)[nH]c1=O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.47
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
KMT2A Q03164 1/20 0.47
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
P2RY2 P41231 3/20 0.41
P2RY4 P51582 1/20 0.41
ALDH1A1 P00352 3/20 0.40
HSD17B10 Q99714 1/20 0.39
RNASE1 P07998 1/20 0.38
P2RY12 Q9H244 1/20 0.38
POLA1 P09884 1/20 0.37
NPC1 O15118 1/20 0.37
GAPDH P04406 1/20 0.36
DUT P33316 2/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1828639 1.00 POLB (0.47) POLBMEN1USP2KMT2ACYP3A4
SCHEMBL13471844 1.00 POLB (0.47) POLBMEN1USP2KMT2ACYP3A4
SCHEMBL14853784 1.00 POLB (0.47) POLBMEN1USP2KMT2ACYP3A4
SCHEMBL6422530 1.00 POLB (0.47) POLBMEN1USP2KMT2ACYP3A4
SCHEMBL14929281 0.92 P2RY2 (0.40) POLBMEN1USP2KMT2ACYP3A4
SCHEMBL25579717 0.92 POLB (0.49) POLBMEN1USP2KMT2ACYP3A4
SCHEMBL6468454 0.91 POLB (0.42) POLBMEN1USP2KMT2ACYP3A4
SCHEMBL24371612 0.91 POLB (0.42) POLBMEN1USP2KMT2ACYP3A4
SCHEMBL16571852 0.91 POLB (0.42) POLBMEN1USP2KMT2ACYP3A4
SCHEMBL17724878 0.89 P2RY2 (0.49) POLBMEN1USP2KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167151-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICA NV (BE) 2023-06-01 US disclosed
US-20210139523-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. (US) 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167151-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C2 POLB 169/4885MEN1 4103/4885USP2 4383/4885
US-20210139523-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C2 POLB 169/4885MEN1 4103/4885USP2 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.